Pepto Bismol didn't prevent travelers' diarrhea compared to placebo, small CDC study found
Bismuth subsalicylate, the active ingredient in Pepto Bismol, is often used to treat and prevent diarrhea while traveling — but a new study found it may not help with prevention.
In the study from the Centers for Disease Control and Prevention, "no significant difference" was found for symptoms of loose stool or diarrhea between groups who took the medication for prevention and those who took a placebo.
Since 1939, bismuth subsalicylate has been approved by the Food and Drug Administration for the treatment of diarrhea, heartburn, indigestion, nausea and upset stomach. But, as the authors note, it's also used off-label for the prevention of diarrhea, especially among international travelers.
The study issued questionnaires before, during and after travel to the 270 participants, who had a median age of 32 and planned to travel to Southeast Asia, south central Asia, North Africa or sub-Saharan Africa for 7 to 21 days. Participants were recruited from clinical sites in New York in Massachusetts.
The group given the medication took 4 tablets twice daily during their trip.
The study did have limitations, including not reaching the target sample size. But it did provide the first new data since the 1980s on the potential use of bismuth subsalicylate in diarrhea prevention, according to the study's authors.
"Despite this study not reaching the targeted sample size, there are nonetheless important considerations for healthcare providers conducting pretravel consultations for international travelers," the authors wrote.
The authors also noted further studies are needed to determine if there is a benefit in certain traveler groups or under certain circumstances.
"A larger study might show benefit, although the benefit may be small given the results of this study," they wrote.
Procter & Gamble, the parent company of Pepto Bismol, provided the medication for the study but did not participate in any procedures, the authors noted.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
UBS Shrugs Abbott Laboratories' (ABT) Diagnostic Weakness Affirms ‘Buy' Rating
Abbott Laboratories (NYSE:ABT) is one of the defensive stocks that billionaires are buying amid US trade tariff uncertainty. On July 21, UBS reiterated a 'Buy' rating and a $148 price target on the stock. The bullish stance comes on the heels of the stock coming under pressure following the release of lower fiscal year 2025 sales guidance. The biopharmaceutical company is facing weakness in its diagnostic segment. However, the weakness has not altered UBS's positive stance on the company. That's because the company is experiencing robust growth, with its MedTech division recording 12.2% organic growth in the second quarter, higher than the consensus estimate of 11.2%. In addition, UBS is buoyed by Abbott's 6.9% organic sales growth or 7.5% on excluding COVID diagnostics. The research firm expects robust growth in other segments, including the MedTech pipeline, to offset weakness in the diagnostic segment. Abbott Laboratories (NYSE:ABT) is a global healthcare company focused on creating life-changing technologies and products that span diagnostics, medical devices, nutrition, and branded generic pharmaceuticals. It is focused on improving health and well-being across all stages of life through innovative solutions and a commitment to accessibility. While we acknowledge the potential of ABT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 11 Best 52-Week High Stocks to Buy Now and 10 Best Biotech Stocks to Buy According to Billionaire Steve Cohen. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Wegovy and beyond: Will weight-loss drugs change the way people look at obesity?
Wegovy, the blockbuster weight-loss drug, is now available in Singapore more than two years after it was approved by the Health Sciences Authority. But its arrival here sparks a deeper conversation about who should take it, how it makes us rethink obesity and weight loss, and whether weight-loss drugs are a magic bullet. Earlier in July, pharmaceutical firm Novo Nordisk, which makes Wegovy, announced in a statement that the injectable drug is now available with prescription from any licensed physician at hospitals and clinics across Singapore. The global hype around Wegovy, which is made for weight loss, stemmed from Ozempic, which was created as an anti-diabetic drug. The latter garnered a lot of attention on social media a few years ago after its users, who weren't all diabetics, showed off their considerable weight loss. What connects Wegovy and Ozempic – besides both being made by Novo Nordisk – is that they contain the active ingredient semaglutide. Mimicking the natural hormone glucagon-like peptide-1, semaglutide regulates blood sugar levels, curbs the appetite and induces the sensation of fullness. One of the differences? Wegovy has a higher maximum dosage of 2.4mg than Ozempic's 2mg. While the benefits have been laid out, what should those considering Wegovy look out for? To answer these questions on this episode of The Usual Place, I have: Senior consultant endocrinologist Dr Sue-Anne Toh from Novi Health, a specialist medical clinic and health-tech company. She has more than 20 years of experience in internal medicine, diabetes, and metabolic health. Her patient Farhan Hanis, a 26-year-old university student and a former plus-sized model. He started on Wegovy about two months ago. General practitioner Dr Bosty Chan, who co-founded health telemedicine providers Sire and Dame, which offers weight management as part of a suite of services. Tune in at 12pm SGT/HKT to watch the stream, and share your thoughts on our revamped YouTube channel. Follow The Usual Place Podcast live at noon every Thursday and get notified for new episode drops: Channel: Apple Podcasts: Spotify: YouTube: Source: The Straits Times © SPH Media Limited. Permission required for reproduction Discover how to enjoy other premium articles here
CBS News
2 hours ago
- CBS News
LA County woman given $7,800 parking bill after visit to Glendale hospital
A woman in Los Angeles County was left with a nearly $8,000 parking bill after visiting a local hospital. Cate Daniels said she visited Glendale Memorial Hospital on Friday. After spending 45 minutes in the facility, the parking machine said she entered the lot three years ago and charged her $7,829. She also said the parking attendant accused her of parking there for weeks. "How can, when people are receiving healthcare, something like this happen with any frequency?" she said. "That is appalling. That's my concern. That this is something that is systematic. I don't hear any inclination to correct it." Parking Company of America, which operates the garage, said the charge should not have happened. The hospital also apologized for the charge. They attributed the error to a computer glitch. They said they are in the process of crediting the chargeback.
